148077-69-4

Basic information

• Product Name: 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride
• Synonyms: 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride;4-[(4-Methyl-1-piperazinyl)methyl]benzoyl acid dihydrochloride .1/2H2O;Imatinib-int H
• CAS NO: 148077-69-4
• Molecular Formula: C₁₃H₁₇ClN₂O
• Molecular Weight: 252.74
• EINECS: 1533716-785-6
• Product Categories: Imatinib
• Mol File: 148077-69-4.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 349.857 °C at 760 mmHg
• Flash Point: 165.388 °C
• Appearance: white power
• Density: 1.185
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.567
• PKA: 7.53±0.10(Predicted)
• CAS DataBase Reference: 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride(148077-69-4)
• EPA Substance Registry System: 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride(148077-69-4)

Safety Data

• Hazardous Substances Data: 148077-69-4(Hazardous Substances Data)

Usage

General Description

4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride is a chemical compound with the molecular formula C15H20ClN2O. It is a benzoyl chloride derivative that contains a piperazine functional group and a methyl group. 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride is commonly used in organic synthesis as a building block for the preparation of various pharmaceuticals and organic compounds. It is a reactive and potentially hazardous compound, and should be handled with care in a controlled laboratory environment. Its properties and reactivity make it useful in the synthesis of complex chemical structures, particularly in the pharmaceutical industry.

InChI:InChI=1/C13H17ClN2O/c1-15-6-8-16(9-7-15)10-11-2-4-12(5-3-11)13(14)17/h2-5H,6-10H2,1H3

Upstream product

• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 314268-40-1 4-((4-methylpiperazin-1-yl)methyl)-benzoic acid methyl ester 
• 109-01-3 1-methyl-piperazine 
• 1571-08-0 methyl 4-formylbenzoate 
• 106261-48-7 4-(4-methylpiperazin-1-ylmethyl)benzoic acid 

Downstream Products

• 790299-79-5 masitinib 
• 928165-90-6 N'-(5-bromo-2-cyano-4-pyrimidinyl)-4-[(4-methyl-1-piperazinyl) methyl]-N'-(2-methylpropyl)benzohydrazide trifluoroacetate 
• 1395050-51-7 N₁-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]phenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide 
• 1395050-56-2 N₁-3-[3-methyl-4-([(5-methyl-3-isoxazolyl)amino]carbonylamino)phenyl]-1H-5-pyrazolyl-4-[(4-methylpiperazino)methyl]benzamide 
• 1395051-60-1 N-(3-[4-([(5-ethyl-3-isoxazolyl)amino]carbonylamino)-3-methylphenyl]-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide 

Relevant articles and documents

CAMPTOTHECIN DERIVATIVES WITH A DISULFIDE MOIETY AND A PIPERAZINE MOIETY

This invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof (wherein X, Y, Z and n are defined herein). These compounds are useful in the treatment of diseases mediated by topoisomerase I enzyme such as cancers. The prese

Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors.

PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS

The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula (I) which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.